I read with great interest the study by Baeza-Delgado et al. [1], which assessed the prevalence of elevated non-high-density lipoprotein cholesterol (non-HDL-C) in 820,318 individuals not receiving lipid-lowering therapy at baseline and followed a propensity score-matched subset to evaluate incident diagnoses. The authors provide valuable population-level evidence that individuals meeting their criterion carried a greater baseline burden of metabolic disease and had a higher incidence of type 2 diabetes, hypertension and metabolic dysfunction-associated steatotic liver disease during follow-up.
